IBI3002
As of the edition of 20 October 2026, IBI3002 is a drug known only by a code name: in active development; acts on IL4R and TSLP.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 5, 0 stopped early
- Disease areas
- Immune system; Lungs and airways; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 2 | 2 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Innovent Biologics | Lead sponsor of trials | 2024 to now |